文献速递甲状腺疾病

STRN-ALK表达联合p53缺失驱动甲状腺癌进展与去分化小鼠模型

Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
PubMed 文献 · Thyroid · 2019-08-16

研究构建了甲状腺滤泡细胞同时表达STRN-ALK并双等位失活p53的转基因小鼠,在致甲状腺肿处理或常规饮食下观察肿瘤发生与进展。结果显示小鼠出现PTC、PDTC和ATC,且PDTC可分为两种形态与基因表达不同的亚型,提示PDTC存在两种功能类型。

要点

  • STRN-ALK联合p53缺失小鼠可再现PTC向PDTC及ATC的多步骤去分化过程。
  • 致甲状腺肿处理小鼠6月龄出现甲状腺癌,12月龄外显率达86%。
  • PDTC可分为两型,PDTC1较PDTC2保留更高甲状腺分化基因表达。

核心结论

  • STRN-ALK表达联合p53失活可驱动小鼠甲状腺癌从PTC进展为PDTC和ATC,并发现PDTC存在两种不同组织学与基因表达特征的类型。

研究设计与样本

  • 研究为转基因小鼠模型研究,甲状腺特异性表达STRN-ALK并双等位失活p53,分别给予常规饮食或甲巯咪唑联合高氯酸钠致甲状腺肿处理。
  • 通过超声成像监测肿瘤发生进展,并进行组织学、免疫组化及RNA-Seq和定量RT-PCR基因表达分析。

主要发现

  • 致甲状腺肿处理小鼠6月龄出现首个甲状腺癌,12月龄外显率达86%;常规饮食小鼠18月龄肿瘤发生率为71%。
  • 组织学显示PTC(n=26)、PDTC(n=21)和ATC(n=8)常共存于同一甲状腺,24%病例发生肺转移。
  • PDTC分为PDTC1和PDTC2两型,PDTC1较PDTC2保留更高Tg和Slc5a5(Nis)表达。

临床怎么用

  • 该模型可用于研究甲状腺癌去分化机制及PDTC两种亚型的潜在治疗差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid tumor progression from well-differentiated cancer to poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) involves step-wise dedifferentiation associated with loss of iodine avidity and poor outcomes. ALK fusions, typically STRN-ALK, are found with higher incidence in human PDTC compared with well-differentiated cancer and, as previously shown, can drive the development of murine PDTC. The aim of this study was to evaluate thyroid cancer initiation and progression in mice with concomitant expression of STRN-ALK and inactivation of the tumor suppressor p53 (Trp53) in thyroid follicular cells. Methods: Transgenic mice with thyroid-specific expression of STRN-ALK and biallelic p53 loss were generated and aged on a regular diet or with methimazole and sodium perchlorate goitrogen treatment. Development and progression of thyroid tumors were monitored by using ultrasound imaging, followed by detailed histological and immunohistochemical evaluation. Gene expression analysis was performed on selected tumor samples by using RNA-Seq and quantitative RT-PCR. Results: In mice treated with goitrogen, the first thyroid cancers appeared at 6 months of age, reaching 86% penetrance by the age of 12 months, while a similar rate (71%) of tumor occurrence in mice on regular diet was observed by 18 months of age. Histological examination revealed well-differentiated papillary thyroid carcinomas (PTC) (n = 26), PDTC (n = 21), and ATC (n = 8) that frequently coexisted in the same thyroid gland. The tumors were frequently lethal and associated with the development of lung metastasis in 24% of cases. Histological and immunohistochemical characteristics of these cancers recapitulated tumors seen in humans. Detailed analysis of PDTC revealed two tumor types with distinct cell morphology and immunohistochemical characteristics, designated as PDTC type 1 (PDTC1) and type 2 (PDTC2). Gene expression analysis showed that PDTC1 tumors retained higher expression of thyroid differentiation genes including Tg and Slc5a5 (Nis) as compared with PDTC2 tumors. Conclusions: In this study, we generated a new mouse model of multistep thyroid cancer dedifferentiation with evidence of progression from PTC to PDTC and ATC. Further, PDTC in these mice showed two distinct histologic appearances correlated with levels of expression of thyroid differentiation and iodine metabolism genes, suggesting a possibility of existence of two PDTC types with different functional characteristics and potential implication for therapeutic approaches to these tumors.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Nikitski AV, Rominski SL, Condello V, et al. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. Thyroid. 2019. PMID: 31298630. doi:10.1089/thy.2019.0284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。